| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Top Magn Reson Imaging] 2020 Apr; Vol. 29 (2), pp. 103-114.
- MeSH Terms: Tumor Microenvironment* ; Brain Neoplasms / *diagnostic imaging ; Glioma / *diagnostic imaging ; Magnetic Resonance Imaging / *methods ; Brain / diagnostic imaging ; Brain / pathology ; Brain Neoplasms / pathology ; Glioma / pathology ; Humans
- References: Jain RK, Di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610–622. ; Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249–257. ; Pries AR, Hopfner M, Le Noble F, et al. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 2010; 10:587–593. ; Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225–239. ; Renkin EM. B.W. Zweifach Award lecture. Regulation of the microcirculation. Microvasc Res 1985; 30:251–263. ; Jespersen SN, Ostergaard L. The roles of cerebral blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and metabolism. J Cereb Blood Flow Metab 2012; 32:264–277. ; Ostergaard L, Tietze A, Nielsen T, et al. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res 2013; 73:5618–5624. ; Mouridsen K, Hansen MB, Ostergaard L, et al. Reliable estimation of capillary transit time distributions using DSC-MRI. J Cereb Blood Flow Metab 2014; 34:1511–1521. ; Tietze A, Mouridsen K, Lassen-Ramshad Y, et al. Perfusion MRI derived indices of microvascular shunting and flow control correlate with tumor grade and outcome in patients with cerebral glioma. PLoS One 2015; 10:e0123044. ; Bonekamp D, Mouridsen K, Radbruch A, et al. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma. J Cereb Blood Flow Metab 2017; 37:485–494. ; Stadlbauer A, Mouridsen K, Doerfler A, et al. Recurrence of glioblastoma is associated with elevated microvascular transit time heterogeneity and increased hypoxia. J Cereb Blood Flow Metab 2018; 38:422–432. ; Nabavizadeh SA, Akbari H, Ware JB, et al. Arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma. Sci Rep 2019; 9:8747. ; Mariani L, Schroth G, Wielepp JP, et al. Intratumoral arteriovenous shunting in malignant gliomas. Neurosurgery 2001; 48:353–357. discussion 357–358. ; Mariani L, Haldemann AR, Schroth G. Arteriovenous shunt measurement during endovascular therapy for cerebrospinal lesions. AJNR Am J Neuroradiol 1997; 18:1679–1689. ; Yoshikawa A, Nakada M, Kita D, et al. Visualization of angiographical arteriovenous shunting in perisylvian glioblastomas. Acta Neurochir Wien 2013; 155:715–719. ; Le TT, Fischbein NJ, André JB, et al. Identification of venous signal on arterial spin labeling improves diagnosis of dural arteriovenous fistulas and small arteriovenous malformations. AJNR Am J Neuroradiol 2012; 33:61–68. ; Warburg O. On the origin of cancer cells. Science 1956; 123:309–314. ; Herholz K, Heindel W, Luyten PR, et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992; 31:319–327. ; Terpstra M, Gruetter R, High WB, et al. Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 1998; 58:5083–5088. ; Ziegler A, Von Kienlin M, Decorps M, et al. High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging. Cancer Res 2001; 61:5595–5600. ; Bulik M, Jancalek R, Vanicek J, et al. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg 2013; 115:146–153. ; Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24:1989–1998. ; Li X, Vigneron DB, Cha S, et al. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. AJNR Am J Neuroradiol 2005; 26:760–769. ; Park I, Spielman DM, Josan S, et al. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010; 12:133–144. ; Ross BD, Higgins RJ, Boggan JE, et al. Carbohydrate metabolism of the rat C6 glioma. An in vivo 13C and in vitro 1H magnetic resonance spectroscopy study. NMR Biomed 1988; 1:20–26. ; Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U A 2003; 100:10158–10163. ; Autry AW, Hashizume R, James CD, et al. Measuring tumor metabolism in pediatric diffuse intrinsic pontine glioma using hyperpolarized carbon-13 MR metabolic imaging. Contrast Media Mol Imaging 2018; 2018:3215658. ; Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 2007; 58:1099–1106. ; Chaumeil MM, Larson PE, Yoshihara HA, et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun 2013; 4:2429. ; Day SE, Kettunen MI, Cherukuri MK, et al. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1-13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2011; 65:557–563. ; Park I, Bok R, Ozawa T, et al. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging 2011; 33:1284–1290. ; Venkatesh HS, Chaumeil MM, Ward CS, et al. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol 2012; 14:315–325. ; Michel KA, et al. Hyperpolarized pyruvate MR spectroscopy depicts glycolytic inhibition in a mouse model of glioma. Radiology 2019; 293:168–173. ; Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci Transl Med 2013; 5:198ra108. ; Park I, Larson PEZ, Gordon JW, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med 2018; 80:864–873. ; Park I, Hu S, Bok R, et al. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2013; 70:33–39. ; Miloushev VZ, Granlund KL, Boltyanskiy R, et al. Metabolic imaging of the human brain with hyperpolarized (13)C pyruvate demonstrates (13)C lactate production in brain tumor patients. Cancer Res 2018; 78:3755–3760. ; Bankson JA, Walker CM, Ramirez MS, et al. Kinetic modeling and constrained reconstruction of hyperpolarized [1-13C]-pyruvate offers improved metabolic imaging of tumors. Cancer Res 2015; 75:4708–4717. ; Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson 2000; 143:79–87. ; Van Zijl PC, Yadav NN. Chemical exchange saturation transfer (CEST): what is in a name and what isn’t? Magn Reson Med 2011; 65:927–948. ; Zhou J, Payen JF, Wilson DA, et al. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 2003; 9:1085–1090. ; Zhou J, Lal B, Wilson DA, et al. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 2003; 50:1120–1126. ; Salhotra A, Lal B, Laterra J, et al. Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. NMR Biomed 2008; 21:489–497. ; Zhou J, Blakeley JO, Hua J, et al. Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med 2008; 60:842–849. ; Togao O, Yoshiura T, Keupp J, et al. Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol 2014; 16:441–448. ; Meissner JE, Korzowski A, Regnery S, et al. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T. J Magn Reson Imaging 2019; 50:1268–1277. ; Paech D, Windschuh J, Oberhollenzer J, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol 2018; 20:1661–1671. ; Ma B, Blakeley JO, Hong X, et al. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging 2016; 44:456–462. ; Harris RJ, Cloughesy TF, Liau LM, et al. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. NMR Biomed 2016; 29:1563–1576. ; Harris RJ, Cloughesy TF, Liau LM, et al. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol 2015; 17:1514–1524. ; Yao J, Tan CHP, Schlossman J, et al. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. J Neurooncol 2019; 142:587–595. ; Wang YL, Yao J, Chakhoyan A, et al. Association between tumor acidity and hypervascularity in human gliomas using pH-weighted amine chemical exchange saturation transfer echo-planar imaging and dynamic susceptibility contrast perfusion MRI at 3T. AJNR Am J Neuroradiol 2019; 40:979–986. ; Neal A, Moffat BA, Stein JM, et al. Glutamate weighted imaging contrast in gliomas with 7Tesla magnetic resonance imaging. Neuroimage Clin 2019; 22:101694. ; Dreher C, Oberhollenzer J, Meissner JE, et al. Chemical exchange saturation transfer (CEST) signal intensity at 7T MRI of WHO IV degrees gliomas is dependent on the anatomic location. J Magn Reson Imaging 2019; 49:777–785. ; Pateras IS, Cooks T. Determination of polarization of resident macrophages and their effect on the tumor microenvironment. Methods Mol Biol 2019; 1928:101–112. ; Fujiwara T, Fukushi J, Yamamoto S. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011; 179:1157–1170. ; Cao L, Che X, Qiu X, et al. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cancer Manag Res 2019; 11:6125–6138. ; Lee CH, Espinosa I, Vrijaldenhoven S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008; 14:1423–1430. ; Badie B, Schartner J. Role of microglia in glioma biology. Microsc Res Tech 2001; 54:106–113. ; Kennedy BC, Maier LM, D’Amico R, et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol 2009; 10:11. ; Schiffer D, Mellai M, Bovio E, et al. The neuropathological basis to the functional role of microglia/macrophages in gliomas. Neurol Sci 2017; 38:1571–1577. ; Leblond MM, Pérès EA, Helaine C, et al. M2 macrophages are more resistant than M1 macrophages following radiation therapy in the context of glioblastoma. Oncotarget 2017; 8:72597–72612. ; Poon CC, Sarkar S, Yong VW, et al. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain 2017; 140:1548–1560. ; Aghighi M, Theruvath AJ, Pareek A, et al. Magnetic resonance imaging of tumor-associated macrophages: clinical translation. Clin Cancer Res 2018; 24:4110–4118. ; Iv M, Samghabadi P, Holdsworth S, et al. Quantification of macrophages in high-grade gliomas by using ferumoxytol-enhanced MRI: a pilot study. Radiology 2019; 290:198–206. ; Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 2014; 36:70–83. ; Daldrup-Link HE. Ten things you might not know about iron oxide nanoparticles. Radiology 2017; 284:616–629. ; Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014; 4:650–661. ; Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017; 14:531–548. ; Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59:110–118. ; Ruivo CF, Adem B, Silva M, et al. The biology of cancer exosomes: insights and new perspectives. Cancer Res 2017; 77:6480–6488. ; Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014; 11:145–156. ; Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med 2018; 379:1754–1765. ; Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 2014; 6:247ra101. ; Macarthur KM, Kao GD, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 2014; 74:2152–2159. ; Morishita M, Takahashi Y, Nishikawa M, et al. Pharmacokinetics of exosomes: an important factor for elucidating the biological roles of exosomes and for the development of exosome-based therapeutics. J Pharm Sci 2017; 106:2265–2269. ; Figueroa JM, Skog J, Akers J, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol 2017; 19:1494–1502. ; Evans SM, Putt M, Yang XY, et al. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol 2016; 127:391–400. ; Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37:646–650. ; Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14:985–990. ; Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24. ; Stover DG, Parsons HA, Ha G, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol 2018; 36:543–553. ; Spindler KG, Boysen AK, Pallisgård N, et al. Cell-Free DNA in metastatic colorectal cancer: a systematic review and meta-analysis. Oncologist 2017; 22:1049–1055. ; Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res 2017; 23:116–123. ; Schwaederle MC, Patel SP, Husain H, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 2017; 23:5101–5111. ; Boisselier B, Gállego Pérez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology 2012; 79:1693–1698. ; Panditharatna E, Kilburn LB, Aboian MS, et al. Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. Clin Cancer Res 2018; 24:5850–5859. ; Schwaederle M, Husain H, Fanta PT, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016; 7:9707–9717. ; Piccioni DE, Achrol AS, Kiedrowski LA, et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol 2019; 8:Cns34. ; Bagley S, Nabavizadeh SA, Mays JJ, et al. Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma—a pilot prospective study. Clin Cancer Res 2019; doi: 10.1158/1078-0432.CCR-19-2533. [Epub ahead of print]. (PMID: 10.1158/1078-0432.ccr-19-2533.) ; Hu Y, Ulrich BC, Supplee J, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 2018; 24:4437–4443. ; Chow D, Chang P, Weinberg BD, et al. Imaging genetic heterogeneity in glioblastoma and other glial tumors: review of current methods and future directions. AJR Am J Roentgenol 2018; 210:30–38. ; Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006; 241:839–846. ; Ellingson BM, Sahebjam S, Kim HJ, et al. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol 2014; 35:673–679. ; Aliotta E, Batchala PP, Schiff D, et al. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging. J Neurooncol 2019; 145:257–263. ; Li C, Wang S, Yan JL, et al. Intratumoral heterogeneity of glioblastoma infiltration revealed by joint histogram analysis of diffusion tensor imaging. Neurosurgery 2019; 85:524–534. ; Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 2010; 23:698–710. ; Zhang H, Schneider T, Wheeler-Kingshott CA, et al. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012; 61:1000–1016. ; White NS, Leergaard TB, D’Arceuil H, et al. Probing tissue microstructure with restriction spectrum imaging: histological and theoretical validation. Hum Brain Mapp 2013; 34:327–346. ; Mulkern RV, Zengingonul HP, Robertson RL, et al. Multi-component apparent diffusion coefficients in human brain. NMR Biomed 1999; 12:51–62. ; Hempel JM, Bisdas S, Schittenhelm J, et al. In vivo molecular profiling of human glioma using diffusion kurtosis imaging. J Neurooncol 2017; 131:93–101. ; Hempel JM, Schittenhelm J, Bisdas S, et al. In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice. J Neuroradiol 2018; 45:32–40. ; Van Cauter S, Veraart J, Sijbers J, et al. Gliomas: diffusion kurtosis MR imaging in grading. Radiology 2012; 263:492–501. ; Raab P, Hattingen E, Franz K, et al. Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences. Radiology 2010; 254:876–881. ; White NS, McDonald CR, Farid N, et al. Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using “restriction spectrum imaging”: quantitative comparison with high B-value DWI and ADC. Am J Neuroradiol 2013; 34:958–964. ; Krishnan AP, Karunamuni R, Leyden KM, et al. Restriction spectrum imaging improves risk stratification in patients with glioblastoma. Am J Neuroradiol 2017; 38:882–889. ; McDonald CR, Delfanti RL, Krishnan AP, et al. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro-Oncol 2016; 18:1579–1590. ; Khan UA, Rennert RC, White NS, et al. Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. J Clin Neurosci Off J Neurosurg Soc Australas 2018; 58:136–141. ; Kothari P, White NS, Farid N, et al. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. AJNR Am J Neuroradiol 2013; 34:1752–1757. ; Kadota Y, Hirai T, Azuma M, et al. Differentiation between glioblastoma and solitary brain metastasis using neurite orientation dispersion and density imaging. J Neuroradiol 2018; doi: 10.1016/j.neurad.2018.10.005. [Epub ahead of print]. (PMID: 10.1016/j.neurad.2018.10.005.) ; Cuddapah VA, Robel S, Watkins S, et al. A neurocentric perspective on glioma invasion. Nat Rev Neurosci 2014; 15:455–465. ; Watkins S, Robel S, Kimbrough IF, et al. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun 2014; 5:4196. ; Hou BL, Bradbury M, Peck KK, et al. Effect of brain tumor neovasculature defined by rCBV on BOLD fMRI activation volume in the primary motor cortex. Neuroimage 2006; 32:489–497. ; Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature 2010; 468:232–243. ; Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987; 66:865–874. ; Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992; 34:463–469. ; Fierstra J, Van Niftrik C, Piccirelli M, et al. Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity. Magn Reson Imaging 2018; 45:78–83. ; Hsu YY, Chang CN, Jung SM, et al. Blood oxygenation level-dependent MRI of cerebral gliomas during breath holding. J Magn Reson Imaging JMRI 2004; 19:160–167. ; Liu WC, Feldman SC, Schulder M, et al. The effect of tumour type and distance on activation in the motor cortex. Neuroradiology 2005; 47:813–819. ; Pillai JJ, Zacà D. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors. Technol Cancer Res Treat 2012; 11:361–374. ; Zacà D, Jovicich J, Nadar SR, et al. Cerebrovascular reactivity mapping in patients with low grade gliomas undergoing presurgical sensorimotor mapping with BOLD fMRI. J Magn Reson Imaging JMRI 2014; 40:383–390. ; Jiang Z, Krainik A, David O, et al. Impaired fMRI activation in patients with primary brain tumors. Neuroimage 2010; 52:538–548. ; Schreiber A, Hubbe U, Ziyeh S, et al. The influence of gliomas and nonglial space-occupying lesions on blood-oxygen-level-dependent contrast enhancement. AJNR Am J Neuroradiol 2000; 21:1055–1063. ; Holodny AI, Schulder M, Liu WC, et al. The effect of brain tumors on BOLD functional MR imaging activation in the adjacent motor cortex: implications for image-guided neurosurgery. AJNR Am J Neuroradiol 2000; 21:1415–1422. ; Pillai JJ, Mikulis DJ. Cerebrovascular reactivity mapping: an evolving standard for clinical functional imaging. AJNR Am J Neuroradiol 2015; 36:7–13. ; Ben Bashat D, Artzi M, Ben Ami H, et al. Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain tumors. PLoS One 2012; 7:e49416. ; Chow DS, Horenstein CI, Canoll P, et al. Glioblastoma induces vascular dysregulation in nonenhancing peritumoral regions in humans. Am J Roentgenol 2016; 206:1073–1081. ; Englander ZK, Horenstein CI, Bowden SG, et al. Extent of BOLD vascular dysregulation is greater in diffuse gliomas without isocitrate dehydrogenase 1 R132H mutation. Radiology 2018; 287:965–972. ; Bowden SG, Gill BJA, Englander ZK, et al. Local glioma cells are associated with vascular dysregulation. Am J Neuroradiol 2018; 39:507–514.
- Entry Date(s): Date Created: 20200410 Date Completed: 20200924 Latest Revision: 20210213
- Update Code: 20240513
|
